SmartPeptide
Start Free
Fat LossLimited human evidence

CagriSema

Novo Nordisk's once-weekly combination of cagrilintide (an amylin analog) and semaglutide. Designed to combine appetite suppression (semaglutide) with satiety + meal-size regulation (cagrilintide). REDEFINE-1 Phase 3 showed ~22.7% weight loss at 68 weeks — strong but below pre-trial expectations.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

REDEFINE-1 (Phase 3, n≈3,400, 68 weeks): mean weight reduction of ~22.7% on CagriSema vs. ~16.1% on semaglutide alone and ~3% on placebo. Cardiovascular outcomes trial REDEFINE-3 is ongoing. Awaiting full FDA submission package.

What's still experimental

Not yet FDA-approved. The combination's performance vs. retatrutide in head-to-head comparisons is unknown. Optimal dosing and treatment duration are still being characterized. MASH and CV outcome data are pending.

Anecdotal / community reports

Available only through clinical trials. Forum speculation about 'building your own' by stacking compounded cagrilintide with semaglutide is dangerous — formulation stability, dose ratios, and interaction data are not established outside the Novo formulation.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “CagriSema”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

Source: Published clinical trial

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

Phase 3 trialREDEFINE-1 Phase 3 trial (Novo Nordisk)
Indication studied: Weight management (Phase 3 — not FDA-approved)
Citation: REDEFINE-1 Phase 3 (n≈3,400, 68 weeks)
Typical
2.4mg(2,400 µg)
once weekly · subcutaneous

Cagrilintide 2.4mg + semaglutide 2.4mg combination, target dose after 16-week titration

Open calculator

Notes from the source: Combination product. Doses listed are AFTER 16-week titration ramp.

Important framing: The numbers above are what published trials tested or what FDA-approved labels specify. They are NOT a SmartPeptide recommendation for you. Trial doses come paired with screening, monitoring, and clinician oversight. Always consult a licensed clinician before any peptide use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “CagriSema”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
101
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
6
34 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "cagrisema OR cagrilintide semaglutide"

Europe PMC — 412 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
678
all years
Last 5 years
674
recent activity
Open access
605
freely readable
OA share
89%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
No indexed human-study summaries found for “cagrisema OR (cagrilintide AND semaglutide)” via Semantic Scholar yet. This is normal for very new or research-only compounds.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
6,717
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • Novo Nordisk206 works
  • Novo Nordisk A/S97 works
  • National Natural Science Foundation of China55 works
  • Eli Lilly and Company36 works
  • National Institutes of Health33 works
  • National Institute of Diabetes and Digestive and Kidney Diseases17 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 6 preprints indexed by Europe PMC.

Known risks

GI side effects (class-typical for GLP-1 + amylin combination). Pancreatitis signal (rare, class warning), gallbladder events. Not yet FDA-approved — long-term safety still being characterized.

Reported side effects

Nausea, vomiting, diarrhea, constipation, decreased appetite, injection-site reactions. The amylin component may add mild glucose-related effects.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “CagriSema”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Investigational only. Patients should pursue FDA-approved alternatives under prescriber care until approval.

Questions for your clinician

  • How does CagriSema compare to Retatrutide for my situation?
  • Should I wait for CagriSema approval or start on currently-approved options?
  • What baseline + monitoring labs would you recommend if I enroll in a trial?

Editorially curated references

Discussions about CagriSema

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all CagriSema discussions Native, moderated, no buying or selling